# MRSI to Predict Response to RT/TMZ ± Belinostat in GBM

> **NCT02137759** · PHASE2 · UNKNOWN · sponsor: **Emory University** · enrollment: 29 (actual)

## Conditions studied

- Glioblastoma Multiforme of Brain

## Interventions

- **RADIATION:** Standard Radiation Therapy
- **DRUG:** Standard Temozolomide
- **DRUG:** Belinostat

## Key facts

- **NCT ID:** NCT02137759
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-05-07
- **Primary completion:** 2023-08-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02137759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02137759, "MRSI to Predict Response to RT/TMZ ± Belinostat in GBM". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02137759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*